Drug intelligence / Profile preview

BEM-103

Development stage: Preclinical
Lead developer: Shanghai Benemae Pharmaceutical
Modality: Peptides
Administration: Oral

Overview

BEM-103 is a non-injectable formulation of a glucagon-like peptide-1 receptor (GLP-1R) agonist currently in preclinical development by Shanghai Benemae Pharmaceutical Corporation. Intended for the treatment of obesity and weight management, BEM-103 functions by activating the GLP-1 receptor, mimicking the action of the endogenous incretin hormone GLP-1. This mechanism promotes weight loss by increasing satiety, reducing appetite, and slowing gastric emptying. As a non-injectable (likely oral) therapy, BEM-103 is designed to offer a more convenient alternative to traditional subcutaneous GLP-1 injections, potentially improving patient compliance and long-term adherence in chronic weight management settings.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on BEM-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEM-103.

Explore the full profile